Acquired Company

Onconova Therapeutics, Inc. acquired Trawsfynydd Therapeutics, Inc. in an all-stock merger to form Traws Pharma, Inc.; the combined company began trading on NASDAQ under the ticker TRAW on April 3, 2024.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical enterprise based in Newtown, Pennsylvania, dedicated to pioneering innovative oncology therapies that address critical gaps in cancer treatment. With an advanced pipeline of promising therapies backed by robust research and development, Traws Pharma is well-positioned to enhance patient outcomes in a rapidly evolving healthcare landscape. As the company progresses through key clinical milestones, it represents an appealing investment opportunity for institutional investors seeking to capitalize on transformative solutions in the oncology sector. Show more

Location: 12 PENNS TRAIL, NEWTOWN, PA, UNITED STATES, 18940, Newtown, PA, 18940, USA | Website: https://www.trawspharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

19.42M

52 Wk Range

$0.97 - $7.96

Previous Close

$1.72

Open

$1.79

Volume

110,269

Day Range

$1.79 - $2.01

Enterprise Value

9.242M

Cash

6.42M

Avg Qtr Burn

-4.011M

Insider Ownership

19.93%

Institutional Own.

23.82%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rigosertib + Pembrolizumab Details Melanoma, Skin cancer, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rigosertib Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ratutrelvir (TRX01) Details COVID-19	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRX100 (tivoxavir marboxil) Details Influenza, Viral infection	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narazaciclib + letrozole Details Cancer, Solid tumor/s, Endometrial cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rigosertib + Nivolumab Details Cancer, Non-small cell lung carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narazaciclib (ON 123300) Details Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.